CRISPR Therapeutics Secures $25M in Series A Funds
April 25, 2014
CRISPR Therapeutics, a biopharmaceutical company focused on developing CRISPR-Cas9, a gene-editing technology, has raised $25 million in a Series A investment from Versant Ventures. The company also announced a founding team comprising high-profile experts in diverse fields of science including genome editing, stem cell biology, advanced drug delivery technologies, RNA interference and gene silencing. The funding and the team’s collective expertise will allow CRISPR Therapeutics to translate its technology into important new gene medicines that have the potential to cure serious genetic diseases at the molecular level.
Cas9 is an enzyme that can be easily programmed with RNA to cut DNA at targeted sites within the genome, enabling the deletion, insertion or correction of target genes with surgical precision. It gives scientists and clinicians the ability to mutate genes of interest and to correct specific target genes, in order to tackle both recessive and dominant genetic diseases.